Location History:
- San Diego, CA (US) (1996)
- Irvine, CA (US) (2012 - 2015)
Company Filing History:
Years Active: 1996-2015
Title: Phang-Lang Chen: Innovator in Pharmaceutical Compositions
Introduction
Phang-Lang Chen is a notable inventor based in Irvine, California, recognized for his contributions to the field of pharmaceutical compositions. With a total of four patents to his name, Chen has made significant strides in developing innovative treatments for chronic myelogenous leukemia and other medical conditions.
Latest Patents
Among his latest patents, Chen has developed pharmaceutical compositions that contain an indolyl isoquinoline compound aimed at treating chronic myelogenous leukemia (CML), particularly in cases resistant to imatinib. His work involves administering a Rad51-inhibitor alongside a kinase inhibitor, with the Rad51 inhibitor preferably comprising an indolyl isoquinoline structure. Additionally, he has created compositions and methods designed to disrupt the interaction between BRCA2 and RAD51, which plays a crucial role in DNA repair. These compounds may serve as protective agents for non-neoplastic cells during chemotherapy and as DNA-damage sensitizers for neoplastic cells.
Career Highlights
Phang-Lang Chen has had a distinguished career, working with esteemed institutions such as the University of California and Taivex Therapeutics Corporation. His research has focused on innovative solutions to complex medical challenges, particularly in oncology.
Collaborations
Chen has collaborated with notable colleagues, including Wen-Hwa Lee and Jiewen Zhu, contributing to the advancement of his research and the development of his patented technologies.
Conclusion
Phang-Lang Chen's work in pharmaceutical compositions showcases his dedication to improving treatment options for patients with chronic myelogenous leukemia and other conditions. His innovative approaches and collaborations highlight the importance of research in the medical field.